The FDA’s Mifepristone Decision Has Baffled Both Sides

The Food and Drug Administration’s recent approval of a second generic version of the abortion pill mifepristone has left people on both sides of the reproductive rights fight scrambling to interpret the decision. Could this be a sign that the Trump administration isn’t interested in taking federal action to further restrict abortion access?

Their intense search for meaning behind an otherwise routine regulatory decision illustrates the high anxiety over the future of a drug that is crucial for abortion access in the US — not just for women in states with bans, but for women everywhere.